SYDNEY & AUCKLAND, New Zealand–(BUSINESS WIRE)–As advised in our 7 June announcement
of the trial results, Dr Barry Snow is presenting 81 week+ data
on the safely and clinical effects of NTCELL in patients with
Parkinson’s disease at the 20th International Congress of
Parkinson’s Disease and Movement Disorders in Berlin. The presentation,
in the form of a poster entitled “Safety and clinical effects of NTCELL®
[immunoprotected (alginate-encapsulated) porcine choroid plexus cells
for xenotransplantation] in patients with Parkinson’s disease (PD): 81
to 130 weeks follow-up” takes place at 12 noon Berlin time today.
Dr Snow, Principal Investigator for the trial, said, “This data shows a
striking and significant improvement in all measurements of Parkinson’s
disease in the four patients. Everything we measured has improved.”
Dr Ken Taylor, CEO of LCT, said, “The results of this clinical trial are
consistent with what LCT has found in pre-clinical studies. Moreover
microarray analyses identified that several nerve growth factors and
nerve protective agents are released from NTCELL and this may explain
the improvement observed in all of the measurements of Parkinson’s
disease.”
The poster is available to view here.
For further information: www.lctglobal.com
Contacts
At the Company:
Ken Taylor, +64 9 276 2690
Chief
Executive
Mobile: +64 21 796 000
ktaylor@lctglobal.com
or
Media
Contact:
Botica Butler Raudon Partners
Rachael Joel, +64 9
303 3862
Mobile: +64 21 403 504
rachaelj@botica.co.nz
